Allogeneic stem cell transplant can be a high-risk procedure.
异基因造血干细胞移植是一种高风险的治疗过程。
More information about allogeneic stem cell transplant follows.
关于异体干细胞移植的更多信息如下。
Patients who have an allogeneic stem cell transplant may be cured.
患者若接受异基因造血干细胞移植，则也可能会治愈。
Allogeneic stem cell transplants are used to treat some ALL patients.
异基因造血干细胞移植可用于治疗某些急性淋巴细胞白血病患者。
Objective To explore the role of TJU103 in preventing graft-versus-host disease (GVHD) after allogeneic stem cell transplantation in mice.
目的探讨TJU103对小鼠同种异基因造血干细胞移植模型移植物抗宿主病(GVHD)是否起预防作用。
Post non myeloablative allogeneic stem cell transplantation (NST) patients usually received DLI one times a month, consecutively 1 ~ 4 times.
非去髓性异基因干细胞移植(nst)患者通常在移植后每月输注1次，连续1 ~4次。
Allogeneic stem cell transplantation is the only treatment that can cure CML at this time. This treatment is most successful in younger patients.
异基因造血干细胞移植是目前唯一可以治愈慢粒的疗法，在年轻患者中尤为成功。
Male donor chimerism were found on day 7 and 14 after allogeneic stem cell transplantation by Y-specific sequence and chromosome karyotype analysis.
对异基因外周血造血干细胞移植的猕猴，用Y特异性序列分析法和性别染色体检测法于移植后7及14天均检测到雄性供者嵌合。
Allogeneic stem cell transplants may be used in children who are not doing well or whose AML returns (called a relapse) after high-dose chemotherapy.
若急粒患儿在接受了大剂量化疗后病情未见好转或病情复发，可采用异基因造血干细胞移植进行治疗。
Conclusion TJU103 is capable of markedly inhibiting t cell proliferative response in vitro and can decrease GVHD incidence after allogeneic stem cell transplantation in mice.
结论TJU103不仅可以显著抑制体外t淋巴细胞增殖效应，而且可显著降低小鼠同种异基因造血干细胞移植模型GVHD的发生率。
IMPORTANCE OF THE FIELD: Invasive fungal diseases (IFD) are severe complications in patients receiving immunosuppression after solid organ or allogeneic stem cell transplantation.
研究领域的重要性：侵袭性真菌疾病(IFD)是实体器官或异基因干细胞移植术后接受免疫抑制治疗患者的严重并发症。
Many CML patients cannot have an allogeneic stem cell transplant. Doctors are studying the use of a patient's own stem cells in these cases. This is called an autologous stem cell infusion .
另一种可选疗法是二次移植，就是对患者施以供体淋巴细胞输注（即注入的白细胞为来自原造血干细胞供体的淋巴细胞）。
However, the researchers evaluated younger patients to see if any might be suitable candidates for allogeneic stem-cell transplantation.
不过研究人员对年轻患者进行评估，看是否任何人都适合干细胞异体移植。
Conclusion: Allogeneic peripheral blood stem cell non-myeloablative transplantation can be selectively used in the treatment of metastasis breast cancer.
结论：异基因非清髓性外周血干细胞移植可选择性地应用于晚期乳腺癌的治疗。
To summary and analyze the nursing methods of 200 patients received the allogeneic peripheral blood stem cell transplantation.
对200例异基因外周血造血干细胞移植患者护理措施进行总结和分析。
Objective:To investigate efficacy of unrelated donor allogeneic peripheral blood stem cell transplantation(UD-PBSCT) in treatment of severe aplastic anemia(SAA).
目的：探讨非亲缘供者外周血造血干细胞移植（UD-PBSCT）治疗重型再生障碍性贫血（SAA）的可行性。
The nursing factors are detected which infect allogeneic peripheral blood haematopoietic stem cell infusion in ABO-major incompatible transplantation or ABO-minor incompatible transplantation.
探讨了护理因素对异基因造血干细胞移植中abo血型主要不合和次要不合的干细胞输注的影响。
Objective To understand the risk of invasive fungal infection at phase of preengraft- ment of allogeneic hematopoietic stem cell transplantation(HSCT).
目的提高对异基因造血干细胞移植后早期深部真菌感染风险的认识。
Objective To explore the clinical significance of allogeneic peripheral stem cell transplantation in the treatment of acute radiation sickness.
目的探讨异基因外周血造血干细胞移植在肠型和极重度骨髓型放射病救治中的作用和地位。
Objective To study the role of nonmyeloablative allogeneic peripheral blood stem cell transplantation (NAST) in the treatment of hematological diseases in elderly patients.
目的探讨非清髓异基因外周造血干细胞移植（NAST）在治疗高龄血液病中的作用。
Six trials (807 donors) were eligible: all were substudies, or constituent parts of, larger randomised controlled trials of bone marrow and peripheral blood stem cell allogeneic transplantation.
六个研究（807位捐者）被纳入：全部皆是骨髓或周边血干细胞异体移植之随机对照试验的次分析或是部份组成。
Is the GVHD more severe in the allogeneic peripheral blood stem cell transplantation compared with allogeneic bone marrow transplantation?
异基因外周血干细胞移植中的GVHD比骨髓移植更严重吗？
The aim of this study was to analyze the hematopoietic chimerism after non-myeloablative allogeneic peripheral blood stem cell transplantation (NAPBSCT).
本研究旨在探讨非清髓异基因外周血造血干细胞移植(NAPBSCT)后造血嵌合体的临床意义。
Early diagnosis and rational treatment, allogeneic hematopoietic stem cell transplantation in particular, are the key to the prolongation of survival time of children with erythroleukemia.
尽早诊断、合理治疗；异基因外周血造血干细胞移植是提高该病患儿生存期的关键。
This case supports further investigation into allogeneic-based stem cell therapies for SCI.
这种情况下支持将异体的干细胞治疗脊髓损伤进一步调查。
Objective: To explore the treatment of pure red cell aplasia (PRCA) after ABO-incompatible allogeneic peripheral blood stem cell transplantation.
目的：探讨abo血型不合异基因外周血干细胞移植后纯红细胞再生障碍性贫血(PRCA)的治疗。
Objective: To explore the treatment of pure red cell aplasia (PRCA) after ABO-incompatible allogeneic peripheral blood stem cell transplantation.
目的：探讨abo血型不合异基因外周血干细胞移植后纯红细胞再生障碍性贫血(PRCA)的治疗。
应用推荐